<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-09-03-2026-shutterstock_1161446392-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-09-03-2026-shutterstock_1161446392-430x241.jpg"/>
                                    
                                    <figcaption>The trial demonstrated dose-dependent results at week 48, with patients on 2.4mg achieving a 15.4% weight reduction. Credit: GBALLGIGGSPHOTO / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Sciwind Biosciences has received China’s National Medical Products Administration (NMPA) approval for its Ecnoglutide injection for chronic weight management.</p>



<p>Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist intended for chronic weight management in Chinese adults with obesity or who are overweight.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Ecnoglutide in Obesity </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Ecnoglutide in Type 2 Diabetes </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>It is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment. This mechanism enables potent and sustained weight loss while supporting metabolic improvements and minimising the risk of chronic diseases.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Ecnoglutide’s approval was based on a Phase III clinical trial that was published in <em>The Lancet Diabetes &amp; Endocrinology</em> in June 2025.</p>



<p>The trial demonstrated dose-dependent results at week 48, where patients receiving the highest dose (2.4mg) achieved a mean 15.4% (placebo-adjusted 15.1%) reduction in weight.</p>



<p>Furthermore, 92.8% of participants realised a weight loss of at least 5%, with many surpassing 10% or 15% reductions. Weight loss continued throughout 48 weeks without plateauing.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Participants receiving Ecnoglutide also saw significant improvements across cardiometabolic risk factors such as blood pressure, fasting glucose, insulin levels, haemoglobin A1c (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), lipid profile, and waist circumference.</p>



<p>The treatment led to a notable decrease in uric acid levels, up to 54.3µmol/L, and reduced hyperuricaemia incidence.</p><div id="slot-two"></div>



<p>For those with baseline liver fat content of 8% or above, Ecnoglutide resulted in a mean reduction of -53.1% by week 40 among those on the 2.4mg dose. Liver enzyme concentrations also dropped more than those recorded in the placebo group.</p>



<p>Sciwind Biosciences founder and CEO Dr Hai Pan said: “The approval of Ecnoglutide injection for weight management is an important milestone for Sciwind in the metabolic disease area, and a breakthrough for China’s innovative drugs in the global GLP-1 field.</p>



<p>“As the world’s first approved cAMP-biased GLP-1 receptor agonist, Ecnoglutide injection has now completed its strategic positioning for both weight management and type 2 diabetes indications.”</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

513060

510660

159615

<p>Sciwind has received approval from China's NMPA for Ecnoglutide injection, a GLP-1 receptor agonist aimed at chronic weight management in adults with obesity. The approval follows a Phase III clinical trial published in The Lancet, showing significant weight loss and improvements in cardiometabolic risk factors. Ecnoglutide demonstrated a mean weight reduction of 15.4% at the highest dose, with 92.8% of participants losing at least 5%. Sciwind's CEO highlighted this as a milestone for innovative drugs in the GLP-1 field.</p>

Sciwind secures China’s NMPA approval for Ecnoglutide injection